Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has
been shown to be very effective in lowering the risk of heart failure, is safe and tolerated
in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent
heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and
non-diabetic patients. Although patients with severe chronic kidney disease and ESKD have
very high risk of heart failure and cardiovascular death, they have been excluded from all of
the previous studies. If this medication is found to be well tolerated and safe in dialysis
patients through this study, future clinical studies can evaluate if this medication can also
reduce the risk of heart failure and cardiovascular death in dialysis patients.
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)